journals.iop.org home page electronic journals * User guide   * Site map   | Quick Search:Help  
Physics in Medicine and Biology
Athens/Institutional login
IOP login: Password:   
Create account | Alerts | Contact us
Journals Home | Journals List | EJs Extra | This Journal | Search | Authors | Referees | Librarians | User Options | Help |

Internal fiducial markers can assist dose escalation in treatment of prostate cancer: result of organ motion simulations

M Zhang et al 2006 Phys. Med. Biol. 51 269-285   doi: 10.1088/0031-9155/51/2/006  Help

   PDF (586 KB) | References | Articles citing this article

M Zhang1,2, V Moiseenko1, M Liu1 and T Craig3
1 British Columbia Cancer Center-Fraser Valley Centre, Surrey, British Columbia V3V 1Z2, Canada
2 Department of Physics & Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
3 Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, Ontario M5G 2M9, Canada
E-mail: mzhang@bccancer.bc.ca

Abstract. Use of internal fiducial markers and electronic portal imaging (EPI) to realign patients has been shown to significantly reduce positioning uncertainties in prostate radiation treatment. This creates the possibility of improving the treatment by decreasing the planning target volume (PTV) margin added to the clinical target volume (CTV), which in turn may allow dose escalation. Conformal treatment plans for three prostate cancer patients were evaluated by using different PTV margins with dose prescription of 70 Gy/35 fr initially. Two beam arrangements, 4-field-box (4FB) and 4-field-oblique (4FO), were used. Then, two dose escalation schemes, 74 Gy and 78 Gy, with tighter PTV margins, were chosen from the first simulation and were tested. A Monte Carlo model was developed to simulate the daily geometric uncertainty and calculate the dose to each organ. After the whole treatment, dose–volume histograms were produced and tumour control probability, prostate equivalent uniform dose and the effective dose to critical organs were calculated. By comparing these radiobiological metrics, optimized dose escalation schemes were found. The results show that using internal fiducial markers and EPI, the prescription dose can be escalated to 78 Gy/39 fr with a 4 mm PTV margin. Based on the available dose–response data for intermediate risk prostate patients, this is estimated to result in a 20% increase of local control and significantly reduced rectal complications.

Print publication: Issue 2 (21 January 2006)
Received 22 July 2005, in final form 27 October 2005
Published 21 December 2005

Bookmark and Share Post to CiteUlike | Post to Connotea | Post to Bibsonomy

 


Find related articles






Article options

Authors & Referees

 
Content finder
  Full Search
  Help


  
Setup information is available for Adobe Acrobat.
EndNote, ProCite ® and Reference Manager ® are registered trademarks of ISI Researchsoft.
Copyright © Institute of Physics and IOP Publishing Limited 2009.
Use of this service is subject to compliance with the terms and conditions of use. In particular, reselling and systematic downloading of files is prohibited.
Help: Cookies | Data Protection.